MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus

[1] Cook MB(2009)Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977–2005 Br J Cancer 101 855-859

[2] Chow WH(2009)Epidemiology of esophageal cancer: orient to occident. Effects of chronology, geography and ethnicity J Gastroenterol Hepatol 24 729-735

[3] Devesa SS(2013)Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 24 51-56

[4] Hongo M(2012)Preoperative chemoradiotherapy for esophageal or junctional cancer N Eng J Med 366 2074-2084

[5] Nagasaki Y(2015)Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial Lancet Oncol 16 1090-1098

[6] Shoji T(2015)Esophageal and esophagogastric junction cancers, version 1.2015 J Natl Compr Cancer Netw 13 194-227

[7] Stahl M(2016)Comparison of dosimetric parameters and toxicity in esophageal cancer patients undergoing 3D conformal radiotherapy or VMAT Strahlenther Onkol 192 722-729

[8] Mariette C(2006)The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas Cancer 106 2119-2127

[9] Haustermans K(2005)Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification Ann Surg 242 684-692

[10] Cervantes A(2004)Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial Eur J Surg Oncol 30 963-971

[1] Cook MB(2009)Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977–2005 Br J Cancer 101 855-859

[2] Chow WH(2009)Epidemiology of esophageal cancer: orient to occident. Effects of chronology, geography and ethnicity J Gastroenterol Hepatol 24 729-735

[3] Devesa SS(2013)Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 24 51-56

[4] Hongo M(2012)Preoperative chemoradiotherapy for esophageal or junctional cancer N Eng J Med 366 2074-2084

[5] Nagasaki Y(2015)Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial Lancet Oncol 16 1090-1098

[6] Shoji T(2015)Esophageal and esophagogastric junction cancers, version 1.2015 J Natl Compr Cancer Netw 13 194-227

[7] Stahl M(2016)Comparison of dosimetric parameters and toxicity in esophageal cancer patients undergoing 3D conformal radiotherapy or VMAT Strahlenther Onkol 192 722-729

[8] Mariette C(2006)The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas Cancer 106 2119-2127

[9] Haustermans K(2005)Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification Ann Surg 242 684-692

[10] Cervantes A(2004)Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial Eur J Surg Oncol 30 963-971